This series explores the development and clinical utility of CAR T-cell therapy in treating patients with mantle cell lymphoma.
EP. 1: EP. 1: Exploring CAR T-Cell Therapy in Patients with Mantle Cell Lymphoma
In an interview with Targeted OncologyTM, Leslie, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs, John Theurer Cancer Center, discussed the CAR T-cell product, brexucabtagene autoleucel, and its influence on both MCL and indolent lymphomas.
EP. 2: The Current Role of CAR T-Cell Therapy in Patients With Mantle Cell Lymphoma
EP. 3: Expert Perspectives on the Current Role of CAR-T Cell Therapy in Patients with Mantle Cell Lymphoma (MCL)
Dr Peter Martin discusses the impact of CAR-T cell therapy in patients with MCL and provides a brief review of key efficacy data from the ZUMA-2 trial.
EP. 4: Emerging Treatment Strategies in MCL: The Role of CAR T
EP. 5: Emerging Treatment Strategies for Patients with MCL
Dr Brian Hill discusses the potential use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma (MCL) and reviews emerging treatment options for patients with MCL.
EP. 6: Evolving Role of CAR T-Cell Therapy in Mantle Cell Lymphoma
Brian Hill, MD, discusses the use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma and identifies other novel agents in this setting.
2 Clarke Drive Cranbury, NJ 08512